IXICO plc Contract to Deploy Biosensors in Clinical Trial (6394W)
16 November 2017 - 6:00PM
UK Regulatory
TIDMIXI
RNS Number : 6394W
IXICO plc
16 November 2017
16 November 2017
IXICO plc
("IXICO" or the "Company")
IXICO signs its first contract with a new biopharma customer to
deploy biosensors in a late stage clinical trial for a psychiatric
disorder
Further expansion of IXICO's biopharma customer base and
wearable biosensor technology
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today announces that it has signed a new contract
with another leading biopharmaceutical company to support the use
of wrist worn activity sensors ('wearable biosensors') in a late
stage trial for a psychiatric disorder.
This contract with a new biopharma customer has a value c.
GBP0.75m over a two year term, commencing in November 2017. IXICO
will utilise its biosensor capabilities, combined with its
artificial intelligence data analytics algorithms, to measure
sleep, day time napping, overall daily activity levels and patterns
using data collected from c.200 people at multiple time points.
Furthermore, the study will allow the exploratory digital measures
of patient quality of life to be evaluated alongside standard
clinical measures.
Better measurement of day and night time sleep is of increasing
interest in clinical research and clinical practice. For some
diseases, it provides a measure of disease progression. Disrupted
sleep or daytime somnolence could also represent a side effect of
the medication. This could result in poor medication adherence or
concerns around patient safety. Current methods of measuring sleep,
daytime activity and somnolence typically rely on patient diaries
or the use of rating scales. Continuous data collection using
wearable biosensors has the potential to create more objective and
real world measures of sleep and movement, in a specific context of
use, as required by regulatory authorities.
This is IXICO's second commercial agreement involving wearable
biosensors and follows on from a contract announced on 4 October
2017 to measure sleep disturbance from biosensor data collected
from people with a neurological disorder.
Giulio Cerroni, CEO of IXICO, commented: "We are delighted to
announce this first contract with a new biopharma customer,
providing our wearable biosensor capabilities and technology to
support this late phase clinical trial. This study is focused on
monitoring the treatment of patients with a serious psychiatric
disorder, further supporting our view that wearable biosensors have
broad utility in clinical research in many therapeutic areas. These
two contracts represent an excellent opportunity for IXICO to
provide new, innovative digital technologies as part of our
commercially led growth strategy."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20
Officer 3763 7499
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Edward Mansfield / Anita Ghanekar 7408 4090
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway / Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTBRBDBGUBBGRU
(END) Dow Jones Newswires
November 16, 2017 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024